# Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

> **NCT00631163** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 102 (actual)

## Conditions studied

- Chronic Anemia
- Transfusional Hemosiderosis

## Interventions

- **DRUG:** Deferasirox (ICL670)

## Key facts

- **NCT ID:** NCT00631163
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-01
- **Final completion:** 2012-02
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631163, "Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00631163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*